MedTrace Logo

Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"

NCT03219723 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 560

Last updated 2019-03-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.

Conditions

  • Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other

Interventions

DRUG

Vonoprazan

Vonoprazan tablets

DRUG

Amoxicillin hydrate

Amoxicillin hydrate (potency)

DRUG

Clarithromycin

Clarithromycin (potency)

DRUG

Metronidazole

Metronidazole

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03219723 on ClinicalTrials.gov